BOONE, N.C., Sept. 26, 2025 /PRNewswire/ — Fuse Oncology, a leader in AI-powered oncology workflow solutions, mission is to unify radiation oncology workflows through vendor-agnostic solutions that deliver real-world value. This vision will be on display at ASTRO, where GE HealthCare will feature Fuse solutions in its booth, underscoring the importance of collaboration and interoperability in advancing cancer care.
By seamlessly connecting across platforms, Fuse solutions are designed to improve efficiency, strengthen compliance, and reduce the administrative burden for care teams.
“Our goal is simple: eliminate unnecessary complexity in oncology workflows so that clinicians can spend more time with patients,” said James Bauler, CEO of Fuse Oncology. “By remaining vendor-agnostic, Fuse can deliver measurable improvements in efficiency, compliance, and revenue integrity across the entire ecosystem.”
Proven Impact Across Oncology Workflows
Fuse’s technology is already driving measurable results for cancer centers nationwide:
ASTRO attendees will experience firsthand how Fuse is redefining radiation oncology workflows with interoperable, vendor-agnostic solutions designed to streamline operations and free clinicians to focus on patient care.
About Fuse Oncology
Fuse Oncology is redefining cancer care with AI-powered, interoperable solutions built by industry insiders. Spun out of Cone Health in 2021 and powered by technology licensed from the University of Michigan, Fuse is realizing a bold vision: an end-to-end oncology workflow that enables providers to move at the speed of the patient™. From charge capture and documentation to clinical insights and analytics, Fuse helps oncology practices streamline operations, reduce burnout, and recover missed charges so clinicians can focus on patients, not paperwork.
SOURCE Fuse Oncology, Inc.
Vancouver, British Columbia--(Newsfile Corp. - February 9, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF)…
This groundbreaking discovery has revealed a systemic metabolic dysfunction that creates a toxic exosome cargo…
This groundbreaking discovery has revealed a systemic metabolic dysfunction that creates a toxic exosome cargo…
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint…
Label-verified GaraHerb ingredient disclosures, manufacturing and policy transparency details, and what consumers searching for GaraHerb…
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES…